{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu YL"],"funding":["Kartigen Biomedical Inc."],"pagination":["3029"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8466236"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(18)"],"pubmed_abstract":["Here, we aimed to investigate the safety and preliminary efficacy of Kartigen®, a matrix with autologous bone marrow mesenchymal stem cell-derived chondrocyte precursors embedded in atelocollagen. As a surgical graft, Kartigen® was implanted onto the cartilage defects at the weight-bearing site of the medial femoral condyle of the knee. Fifteen patients were enrolled and stratified into two groups, undergoing either Kartigen® implantation (n = 10) or microfracture (control group, n = 5). The primary endpoint was to evaluate the safety of Kartigen® by monitoring the occurrence of adverse events through physician queries, physical examinations, laboratory tests, and radiological analyses for 2 years. There were no infections, inflammations, adhesions, loose body, or tumor formations in the K"],"journal":["Polymers"],"pubmed_title":["Safety and Efficacy of Kartigen® in Treating Cartilage Defects: A Randomized, Controlled, Phase I Trial."],"pmcid":["PMC8466236"],"funding_grant_id":["NA"],"pubmed_authors":["Liu TT","Liu YL","Shih TT","Chang CH","Wang JH","Yang MC","Lin FH","Liu HC","Yen CC"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Efficacy of Kartigen® in Treating Cartilage Defects: A Randomized, Controlled, Phase I Trial.","description":"Here, we aimed to investigate the safety and preliminary efficacy of Kartigen®, a matrix with autologous bone marrow mesenchymal stem cell-derived chondrocyte precursors embedded in atelocollagen. As a surgical graft, Kartigen® was implanted onto the cartilage defects at the weight-bearing site of the medial femoral condyle of the knee. Fifteen patients were enrolled and stratified into two groups, undergoing either Kartigen® implantation (n = 10) or microfracture (control group, n = 5). The primary endpoint was to evaluate the safety of Kartigen® by monitoring the occurrence of adverse events through physician queries, physical examinations, laboratory tests, and radiological analyses for 2 years. There were no infections, inflammations, adhesions, loose body, or tumor formations in the K","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-22T07:56:44.562Z","creation":"2022-02-11T11:27:58.834Z"},"accession":"S-EPMC8466236","cross_references":{"pubmed":["34577930"],"doi":["10.3390/polym13183029"]}}